Regenerative medicine as a disruptive technology: Implications for manufacturing and clinical adoption

Research output: Contribution to journalArticlepeer-review

Abstract

Although regenerative medicine has been described as a disruptive innovation, there has been little critical enquiry into the nature and location of the disruption. This paper, based on ten cases in the UK, analyses the nature of disruption for allogeneic and autologous therapies in terms of manufacturing, distribution and adoption in clinical settings. We discuss the challenges of dealing with inherent variability in living systems and how this necessitates co-evolution of technologies and innovations. We propose that understanding of the distinction between disruptive and incremental innovation, and of the nature, extent and location of the disruption across sectoral value chains, can help to guide company innovation strategies and government innovation support policies for regenerative medicine, as already proposed for industrial biotechnology.
Original languageEnglish
Pages (from-to)1287-1303
Number of pages17
JournalCell and Gene Therapy Insights
Volume5
Issue number10
Early online date21 Oct 2019
DOIs
Publication statusPublished - 23 Oct 2019

Fingerprint Dive into the research topics of 'Regenerative medicine as a disruptive technology: Implications for manufacturing and clinical adoption'. Together they form a unique fingerprint.

Cite this